MI-EATON
23.9.2021 12:32:11 CEST | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has introduced a new zero-leak Compact Combo Valve that safely vents harmful evaporative fuel vapors in the tank by stacking a Fill Limit Vent Valve (FLVV) and a new Zero-Leak Grade Vent Valve (GVV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005077/en/
A key benefit of the Compact Combo is reduced fuel vapor permeation. The smaller footprint of the stacked valves allows for a tighter seal when welded to the tank, in turn reducing permeation.
This innovative configuration reduces the product’s footprint by 20 mm, which decreases potential leak paths and provides fuel tank manufacturers more design flexibility. The Zero-Leak GVV fulfills all government-mandated requirements for zero-leak vapor valves.
“Eaton's world-class engineering teams are leading the way in developing innovative and highly efficient fuel vapor management products,” said Brian Contat, business unit director, Fuel Emissions, Eaton’s Vehicle Group. “As evaporative emissions reduction and vehicle standards become more stringent, Eaton’s fuel emissions products deliver a competitive advantage worldwide that helps our customers achieve or exceed upcoming emissions regulations.”
New Compact Combo technology reduces hydrocarbon emissions during refueling
The new Compact Combo Valve technology reduces hydrocarbon emissions with 98 percent efficiency during the vehicle refueling process and allows manufacturers to meet vehicle hydrocarbon emissions standards while the vehicle is parked.
The Compact Combo Valve has several unique design features that increase valve functionality to meet both tank and customer requirements. These features include a seal that reduces liquid leak in static venting conditions, as well as the ability to change the shut-off height of the FLVV through component substitution. Eaton also offers an added slosh baffle feature for vehicle applications involving aggressive driving dynamics that may cause shifting liquid fuel to leak.
“We can use short or long FLVV housings, depending on the application, for maximum permeation reduction,” Contat said. “We are able to cover all shut-off height requirements to vent above the shut-off valve when the main refueling valve is closed and the GVV shut-off height remains constant and optimized.”
Zero-Leak GVV prevents fuel leakage in all conditions
The GVV’s position at the top of the fuel tank prevents liquid leakage during all situations, including when the vehicle is traveling or parked at an angle. This is an added benefit when compared with competitive technologies that do not allow optimized positioning within the fuel tank during such conditions.
“Our design gives customers greater freedom to perform grade venting, which allows manufacturers to meet zero-leak vapor valve requirements,” Contat said. “You have to ensure you’re venting during all normal vehicle operations and degrees of parking.”
The zero-leak vapor valve requirement is an industry requisite to meet vehicle safety, driveability, emissions and component durability specifications. Eaton’s new Zero-Leak GVV sealing methodology employs an elastomeric seal over-molded onto a substrate to ensure this requirement is met.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005077/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 08:30:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
